Get the Stockscreener App
6.32
1.86%
-0.12
Silence Therapeutics Plc Adr stock is traded at $6.32, with a volume of 155.85K.
It is down -1.86% in the last 24 hours and down -6.09% over the past month.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
See More
Previous Close:
$6.44
Open:
$6.44
24h Volume:
155.85K
Relative Volume:
0.82
Market Cap:
$298.52M
Revenue:
$31.37M
Net Income/Loss:
$-53.77M
P/E Ratio:
-4.3475
EPS:
-1.4537
Net Cash Flow:
$-49.02M
1W Performance:
-9.20%
1M Performance:
-6.09%
6M Performance:
+13.16%
1Y Performance:
-4.24%
1-Day Range:
$6.20
$6.51
1-Week Range:
$5.95
$7.10
52-Week Range:
$1.97
$8.08
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Name
Silence Therapeutics Plc Adr
Sector
Industry
Phone
44-0-20-3457 6900
Address
12 HAMMERSMITH GROVE, LONDON
Compare SLN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
6.32 | 304.19M | 31.37M | -53.77M | -49.02M | -1.4537 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Goldman | Sell |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Stock (SLN) Latest News
Frazier Life Sciences Management L.P. Decreases Holdings in Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
Does Silence Therapeutics Plc ADR (SLN) offer a good opportunity for investors? - setenews.com
Saturn V Capital Management LP Lowers Position in Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Silence Therapeutics Plc ADR (SLN) is looking forward to a strong quarter - Setenews
Falcon’s Beyond Global Inc (FBYD) expanding its growth trajectory ahead - setenews.com
Net current asset value per share of Silence Therapeutics PLC Sponsored ADR – FWB:XRP2 - TradingView
HC Wainwright Has Bullish Forecast for SLN FY2025 Earnings - Defense World
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Barchart.com
Brokerages Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) PT at $32.60 - Defense World
SLN: Revenue fell, net loss widened, and cash will fund operations into 2028, but more funding needed - TradingView
Silence Therapeutics (SLN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Silence Therapeutics (NASDAQ:SLN) Stock Price Down 2.1%Time to Sell? - MarketBeat
Our approach to nucleotide-based therapeutics - AstraZeneca
5 Under-the-Radar Biotech Stocks That Could Soar in 2026 - Barchart.com
Silence Therapeutics completes enrollment in PV treatment study - Investing.com
Check Out Insider Trades For Silence Therapeutics Plc ADR (SLN) Stock - fostersleader.com
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Average Price Target from Analysts - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
GAMMA Investing LLC Buys 4,773 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Goldman Sachs Group Inc. Sells 12,510 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Consensus Target Price from Analysts - Defense World
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire Inc.
Silence Therapeutics (OTCMKTS:SLNCF) Shares Down 5% – Here’s What Happened - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Silence Therapeutics (SLN) Stock Price, News & Analysis - MarketBeat
Silence Therapeutics director Michael Davidson resigns from board - Investing.com
Silence Therapeutics director Michael Davidson resigns from board By Investing.com - Investing.com India
William Blair Issues Pessimistic Forecast for SLN Earnings - Defense World
Silence Therapeutics earnings missed by $0.06, revenue fell short of estimates - Investing.com South Africa
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $33.83 Average PT from Analysts - Defense World
Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade - Yahoo.co
Stephens Inc. AR Invests $260,000 in Evergy Inc. (NASDAQ:EVRG) - Defense World
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Price Up 20.7% – Still a Buy? - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus - Nasdaq
Silence Therapeutics soars 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com
H.C. Wainwright reiterates buy rating on Silence Therapeutics stock By Investing.com - Investing.com South Africa
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - Nasdaq
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - Yahoo Finance
Silence Therapeutics stock hits 52-week low at $3.19 - Investing.com
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know - Nasdaq
Earnings call transcript: Silence Therapeutics sees stock rise post-earnings - Investing.com
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - Nasdaq
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
Silence Therapeutics stock holds Buy rating on positive trial results By Investing.com - Investing.com UK
Silence Therapeutics director Alistair Gray retires - Investing.com
Zerlasiran shows promise in lowering cardiovascular risk - Investing.com
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look - Seeking Alpha
Silence Therapeutics Plc Adr Stock (SLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):